[1]
Yan, B. Carboxylesterases. Encycl. Drug Metab. Interact., 2012, 1, 423-456.
[2]
Laizure, S.C.; Herring, V.; Hu, Z.; Witbrodt, K.; Parker, R.B. The role of human carboxylesterases in drug metabolism: Have we overlooked their importance? Pharmacotherapy, 2013, 33, 210-222.
[3]
Hatfield, M.J.; Potter, P.M. Carboxylesterase inhibitors. Expert Opin. Ther. Pat., 2011, 21, 1159-1171.
[4]
Di, L.; Kerns, E.H. Drug-Like Properties: Concepts, Structure Design, and Methods; Elevier: London, UK, 2016.
[5]
Ettmayer, P.; Amidon, G.L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem., 2004, 47, 2393-2404.
[6]
Merali, Z.; Ross, S.; Pare, G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol. Drug Interact., 2014, 29, 143-151.
[7]
Satoh, T.; Hosokawa, M. Structure, function and regulation of carboxylesterases. Chem. Biol. Interact., 2006, 162, 195-211.
[8]
Satoh, T.; Hosokawa, M. Carboxylesterases: Structure, function and polymorphism. Biomol. Ther., 2009, 17, 335-347.
[9]
Redinbo, M.R.; Bencharit, S.; Potter, P.M. Human carboxylesterase 1: From drug metabolism to drug discovery. Biochem. Soc. Trans., 2003, 31, 620-624.
[10]
Sweeney, R.E.; Maxwell, D.M. A theoretical model of the competition between hydrolase and carboxylesterase in protection against organophosphorus poisoning. Math. Biosci., 1999, 160, 175-190.
[11]
Broomfield, C.A.; Kirby, S.D. Progress on the road to new nerve agent treatments. J. Appl. Toxicol., 2001, 21, S43-S46.
[12]
Maxwell, D.M.; Brecht, K.M. Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds. J. Appl. Toxicol., 2001, 21, S103-S107.
[13]
Bencharit, S.; Morton, C.L.; Xue, Y.; Potter, P.M.; Redinbo, M.R. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol., 2003, 10, 349-356.
[14]
Wang, D-D.; Zou, L-W.; Jin, Q.; Hou, J.; Ge, G-B.; Yang, L. Recent progress in the discovery of natural inhibitors against human carboxylesterases. Fitoterapia, 2017, 117, 84-95.
[15]
Redinbo, M.R.; Potter, P.M. Keynote review: Mammalian carboxylesterases: From drug targets to protein therapeutics. Drug Discov. Today, 2005, 10, 313-325.
[16]
Zou, L-W.; Jin, Q.; Wang, D-D.; Qian, Q-K.; Ge, G-B.; Yang, L.; Hao, D-C. Carboxylesterase inhibitors: An update. Curr. Med. Chem., 2018, 25(14), 1627-1649.
[18]
Parker, R.B.; Hu, Z-Y.; Meibohm, B.; Laizure, S.C. Effects of alcohol on human carboxylesterase drug metabolism. Clin. Pharmacokinet., 2015, 54, 627-638.
[19]
Ross, M.K.; Crow, J.A. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J. Biochem. Mol. Toxicol., 2007, 21, 187-196.
[20]
Sato, Y.; Miyashita, A.; Iwatsubo, T.; Usui, T. Simultaneous absolute protein quantification of carboxylesterases 1 and 2 in human liver tissue fractions using liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos., 2012, 40, 1389-1396.
[21]
Potter, P.M.; Wolverton, J.S.; Morton, C.L.; Wierdl, M.; Danks, M.K. Cellular localization domains of a rabbit and a human carboxylesterase: Influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res., 1998, 58, 3627-3632.
[22]
Robbi, M.; Beaufay, H. The COOH terminus of several liver carboxylesterases targets these enzymes to the lumen of the endoplasmic reticulum. J. Biol. Chem., 1991, 266, 20498-20503.
[23]
Bencharit, S.; Morton, C.L.; Howard-Williams, E.L.; Danks, M.K.; Potter, P.M.; Redinbo, M.R. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat. Struct. Biol., 2002, 9, 337-342.
[24]
Bencharit, S.; Morton, C.L.; Xue, Y.; Potter, P.M.; Redinbo, M.R. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme [Erratum to document cited in CA139:65362]. Nat. Struct. Biol., 2003, 10, 577.
[25]
Bencharit, S.; Morton, C.L.; Hyatt, J.L.; Kuhn, P.; Danks, M.K.; Potter, P.M.; Redinbo, M.R. Crystal structure of human carboxylesterase 1 complexed with the alzheimer’s drug tacrine: From binding promiscuity to selective inhibition. Chem. Biol., 2003, 10, 341-349.
[26]
Fleming, C.D.; Edwards, C.C.; Kirby, S.D.; Maxwell, D.M.; Potter, P.M.; Cerasoli, D.M.; Redinbo, M.R. Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare Agents Soman and Tabun. Biochemistry, 2007, 46, 5063-5071.
[27]
Argikar, U.A.; Potter, P.M.; Hutzler, J.M.; Marathe, P.H. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: Focus on reaction phenotyping and prediction of human clearance. AAPS J., 2016, 18, 1391-1405.
[28]
Xu, J.; Xu, Y.; Xu, Y.; Yin, L.; Zhang, Y.; Xu, J. Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr (-/-) mice. Sci. Rep., 2017, 7, 17845.
[29]
Ross, M.K.; Streit, T.M.; Herring, K.L. Carboxylesterases: Dual roles in lipid and pesticide metabolism. J. Pestic. Sci., 2010, 35, 257-264.
[30]
Hosokawa, M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules, 2008, 13, 412-431.
[31]
Di, L. The role of drug metabolizing enzymes in clearance. Expert Opin. Drug Metab. Toxicol., 2014, 10, 379-393.
[32]
Na, K.; Lee, E-Y.; Lee, H-J.; Kim, K-Y.; Lee, H.; Jeong, S-K.; Jeong, A-S.; Cho, S.Y.; Kim, S.A.; Song, S.Y.; Kim, K.S.; Cho, S.W.; Kim, H.; Paik, Y-K. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics, 2009, 9, 3989-3999.
[33]
Zhen, L.; Rusiniak, M.E.; Swank, R.T. The β-glucuronidase propeptide contains a serpin-related octamer necessary for complex formation with egasyn esterase and for retention within the endoplasmic reticulum. J. Biol. Chem., 1995, 270, 11912-11920.
[34]
Tabata, T.; Katoh, M.; Tokudome, S.; Nakajima, M.; Yokoi, T. Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab. Dispos., 2004, 32, 1103-1110.
[35]
Xu, G.; Zhang, W.; Ma, M.K.; McLeod, H.L. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res., 2002, 8, 2605-2611.
[36]
Hines, R.N.; Simpson, P.M.; McCarver, D.G. Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny. Drug Metab. Dispos., 2016, 44, 959-966.
[37]
Fleming, C.D.; Bencharit, S.; Edwards, C.C.; Hyatt, J.L.; Tsurkan, L.; Bai, F.; Fraga, C.; Morton, C.L.; Howard-Williams, E.L.; Potter, P.M.; Redinbo, M.R. Structural insights into drug processing by human carboxylesterase 1: Tamoxifen, mevastatin, and inhibition by benzil. J. Mol. Biol., 2005, 352, 165-177.
[39]
Wang, X.; Liang, Y.; Liu, L.; Shi, J.; Zhu, H-J. Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI). Rapid Commun. Mass Spectrom., 2016, 30, 553-561.
[40]
Boberg, M.; Vrana, M.; Mehrotra, A.; Pearce, R.E.; Gaedigk, A.; Bhatt, D.K.; Leeder, J.S.; Prasad, B. Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants. Drug Metab. Dispos., 2017, 45, 216-223.
[41]
Wegler, C.; Gaugaz, F.Z.; Andersson, T.B.; Wisniewski, J.R.; Busch, D.; Groeer, C.; Oswald, S.; Noren, A.; Weiss, F.; Hammer, H.S.; Joos, T.O.; Poetz, O.; Achour, B.; Rostami-Hodjegan, A.; Van De Steeg, E.; Wortelboer, H.M.; Artursson, P. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Mol. Pharmaceutics., 2017, 14, 3142-3151.
[42]
Sun, A.; Jiang, Y.; Wang, X.; Liu, Q.; Zhong, F.; He, Q.; Guan, W.; Li, H.; Sun, Y.; Shi, L.; Yu, H.; Yang, D.; Xu, Y.; Song, Y.; Tong, W.; Li, D.; Lin, C.; Hao, Y.; Geng, C.; Yun, D.; Zhang, X.; Yuan, X.; Chen, P.; Zhu, Y.; Li, Y.; Liang, S.; Zhao, X.; Liu, S.; He, F. Liverbase: A comprehensive view of human liver biology. J. Proteome Res., 2010, 9, 50-58.
[44]
Williams, E.T.; Bacon, J.A.; Bender, D.M.; Lowinger, J.J.; Guo, W-K.; Ehsani, M.E.; Wang, X.; Wang, H.; Qian, Y-W.; Ruterbories, K.J.; Wrighton, S.A.; Perkins, E.J. Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab. Dispos., 2011, 39, 2305-2313.
[45]
Oda, S.; Fukami, T.; Yokoi, T.; Nakajima, M. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab. Pharmacokinet., 2015, 30, 30-51.
[46]
Bahar, F.G.; Ohura, K.; Ogihara, T.; Imai, T. Species difference of esterase expression and hydrolase activity in plasma. J. Pharm. Sci., 2012, 101, 3979-3988.
[47]
Li, B.; Sedlacek, M.; Manoharan, I.; Boopathy, R.; Duysen, E.G.; Masson, P.; Lockridge, O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol., 2005, 70, 1673-1684.
[48]
Morton, C.L.; Iacono, L.; Hyatt, J.L.; Taylor, K.R.; Cheshire, P.J.; Houghton, P.J.; Danks, M.K.; Stewart, C.F.; Potter, P.M. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother. Pharmacol., 2005, 56, 629-636.
[49]
Soares, E.R. Identification of a new allele of Es-I segregating in an inbred strain of mice. Biochem. Genet., 1979, 17, 577-583.
[50]
Williams, F.M. Clinical significance of esterases in man. Clin. Pharmacokinet., 1985, 10, 392-403.
[51]
Zhu, H-J.; Patrick, K.S.; Yuan, H-J.; Wang, J-S.; Donovan, J.L.; DeVane, C.L.; Malcolm, R.; Johnson, J.A.; Youngblood, G.L.; Sweet, D.H.; Langaee, T.Y.; Markowitz, J.S. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: Clinical significance and molecular basis. Am. J. Hum. Genet., 2008, 82, 1241-1248.
[52]
Ribelles, N.; Lopez-Siles, J.; Sanchez, A.; Gonzalez, E.; Sanchez, M.J.; Carbantes, F.; Sanchez-Rovira, P.; Marquez, A.; Duenas, R.; Sevilla, I.; Alba, E. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr. Drug Metab., 2008, 9, 336-343.
[53]
Kubo, T.; Kim, S-R.; Sai, K.; Saito, Y.; Nakajima, T.; Matsumoto, K.; Saito, H.; Shirao, K.; Yamamoto, N.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Ohno, Y.; Ozawa, S.; Sawada, J-I. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab. Dispos., 2005, 33, 1482-1487.
[54]
Geshi, E.; Kimura, T.; Yoshimura, M.; Suzuki, H.; Koba, S.; Sakai, T.; Saito, T.; Koga, A.; Muramatsu, M.; Katagiri, T. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens. Res., 2005, 28, 719-725.
[55]
Sanghani, S.P.; Sanghani, P.C.; Schiel, M.A.; Bosron, W.F. Human carboxylesterases: an update on CES1, CES2 and CES3. Protein Pept. Lett., 2009, 16, 1207-1214.
[56]
Wang, X.; Rida, N.; Shi, J.; Wu Audrey, H.; Bleske Barry, E.; Zhu, H.J. A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab. Dispos., 2017, 45, 1149-1155.
[57]
Charasson, V.; Bellott, R.; Meynard, D.; Longy, M.; Gorry, P.; Robert, J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin. Pharmacol. Ther., 2004, 76, 528-535.
[58]
Zhu, W.; Song, L.; Zhang, H.; Matoney, L.; Lecluyse, E.; Yan, B. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab. Dispos., 2000, 28, 186-191.
[59]
Yang, J.; Shi, D.; Yang, D.; Song, X.; Yan, B. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol. Pharmacol., 2007, 72, 686-694.
[60]
Zhu, H-J.; Appel, D.I.; Jiang, Y.; Markowitz, J.S. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab. Dispos., 2009, 37, 1819-1825.
[61]
Yang, J.; Yan, B. Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: Evidence on an involvement of the pregnane X receptor. Toxicol. Sci., 2007, 95, 13-22.
[62]
Staudinger, J.L.; Xu, C.; Cui, Y.J.; Klaassen, C.D. Nuclear receptor-mediated regulation of carboxylesterase expression and activity. Expert Opin. Drug Metab. Toxicol., 2010, 6, 261-271.
[63]
Furihata, T.; Hosokawa, M.; Masuda, M.; Satoh, T.; Chiba, K. Hepatocyte nuclear factor-4α plays pivotal roles in the regulation of mouse carboxylesterase 2 gene transcription in mouse liver. Arch. Biochem. Biophys., 2006, 447, 107-117.
[64]
Cui, J.Y.; Li, C.Y. Regulation of Xenobiotic Metabolism in the Liver. In: Comprehensive Toxicology; 3rd ed.; McQueen, C.A., Ed.
Amsterdam: Elservier, 2018.
[65]
Maruichi, T.; Fukami, T.; Nakajima, M.; Yokoi, T. Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). Biochem. Pharmacol., 2010, 79, 288-295.
[66]
Yang, D.; Pearce, R.E.; Wang, X.; Gaedigk, R.; Wan, Y-J.Y.; Yan, B. Human carboxylesterases HCE1 and HCE2: Ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol., 2009, 77, 238-247.
[67]
Shi, D.; Yang, D.; Prinssen, E.P.; Davies, B.E.; Yan, B. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J. Infect. Dis., 2011, 203, 937-942.
[68]
Chen, Y-T.; Trzoss, L.; Yang, D.; Yan, B. Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: Postnatal surge and organ-dependent regulation. Toxicology, 2015, 330, 55-61.
[69]
Hines, R.N. Age-dependent expression of human drug-metabolizing enzymes. In: Encyclopedia of Drug Metabolism and Interactions; Lyubimov, A.V.; Rodrigues, A.D.; Sinz, M.A., Eds.; New Jersey: John Wiley & Sons, 2012, Vol. 4, pp. 451-483.
[70]
Dalvi Prashant, S.; Singh, A.; Trivedi Hiren, R.; Mistry Suresh, D.; Vyas Bhadresh, R. Adverse drug reaction profile of oseltamivir in children. J. Pharmacol. Pharmacother., 2011, 2, 100-103.
[71]
Vree, T.B.; Dammers, E.; Ulc, I.; Horkovics-Kovats, S.; Ryska, M.; Merkx, I. Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: Gut hydrolysis of lovastatin is twice that of simvastatin. Sci. World J., 2003, 3, 1332-1343.
[72]
Patrick, K.S.; Straughn, A.B.; Minhinnett, R.R.; Yeatts, S.D.; Herrin, A.E.; DeVane, C.L.; Malcolm, R.; Janis, G.C.; Markowitz, J.S. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 2007, 81, 346-353.
[73]
Shi, J.; Wang, X.; Eyler, R.F.; Liang, Y.; Liu, L.; Mueller, B.A.; Zhu, H-J. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic Clin. Pharmacol. Toxicol., 2016, 119, 555-561.
[74]
Robinson, R.P.; Bartlett, J.A.; Bertinato, P.; Bessire, A.J.; Cosgrove, J.; Foley, P.M.; Manion, T.B.; Minich, M.L.; Ramos, B.; Reese, M.R.; Schmahai, T.J.; Swick, A.G.; Tess, D.A.; Vaz, A.; Wolford, A. Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide. Bioorg. Med. Chem. Lett., 2011, 21, 4150-4154.
[75]
McClure, K.F.; Piotrowski, D.W.; Petersen, D.; Wei, L.; Xiao, J.; Londregan, A.T.; Kamlet, A.S.; Dechert-Schmitt, A-M.; Raymer, B.; Ruggeri, R.B.; Canterbury, D.; Limberakis, C.; Liras, S.; DaSilva-Jardine, P.; Dullea, R.G.; Loria, P.M.; Reidich, B.; Salatto, C.T.; Eng, H.; Kimoto, E.; Atkinson, K.; King-Ahmad, A.; Scott, D.; Beaumont, K.; Chabot, J.R.; Bolt, M.W.; Maresca, K.; Dahl, K.; Arakawa, R.; Takano, A.; Halldin, C. Liver-targeted small-molecule inhibitors of proprotein convertase subtilisin/kexin type 9 Synthesis. Angew. Chem. Int. Ed. Engl., 2017, 56, 16218-16222.
[76]
Williams, E.T.; Ehsani, M.E.; Wang, X.; Wang, H.; Qian, Y-W.; Wrighton, S.A.; Perkins, E.J. Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases. J. Pharmacol. Toxicol. Methods, 2008, 57, 138-144.
[77]
Imai, T.; Ohura, K. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr. Drug Metab., 2010, 11, 793-805.
[78]
Trapa, P.E.; Beaumont, K.; Atkinson, K.; Eng, H.; King-Ahmad, A.; Scott, D.O.; Maurer, T.S.; Di, L. In vitro-In vivo extrapolation of intestinal availability for carboxylesterase substrates using portal vein-cannulated monkey. J. Pharm. Sci., 2017, 106, 898-905.
[79]
Dokoumetzidis, A.; Kalantzi, L.; Fotaki, N. Predictive models for oral drug absorption: From in silico methods to integrated dynamical models. Expert Opin. Drug Metab. Toxicol., 2007, 3, 491-505.
[80]
Yang, J.; Jamei, M.; Yeo, K.R.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 2007, 8, 676-684.
[81]
Benet, L.Z.; Izumi, T.; Zhang, Y.; Silverman, J.A.; Wacher, V.J. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Release, 1999, 62, 25-31.
[82]
Karlsson, F.H.; Bouchene, S.; Hilgendorf, C.; Dolgos, H.; Peters, S.A. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development. Drug Metab. Dispos., 2013, 41, 2033-2046.
[83]
Nishimuta, H.; Sato, K.; Yabuki, M.; Komuro, S. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab. Pharmacokinet., 2011, 26, 592-601.
[84]
Gertz, M.; Harrison, A.; Houston, J.B.; Galetin, A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 2010, 38, 1147-1158.
[85]
Fung, E.N.; Zheng, N.; Arnold, M.E.; Zeng, J. Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS. Bioanalysis, 2010, 2, 733-743.
[86]
Zheng, N.; Fung, E.N.; Buzescu, A.; Arnold, M.E.; Zeng, J. Esterase inhibitors as ester-containing drug stabilizers and their hydrolytic products: Potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2012, 26, 1291-1304.
[87]
Taketani, M.; Shii, M.; Ohura, K.; Ninomiya, S.; Imai, T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci., 2007, 81, 924-932.
[88]
Holenarsipur, V.K.; Gaud, N.; Sinha, J.; Sivaprasad, S.; Bhutani, P.; Subramanian, M.; Singh, S.P.; Arla, R.; Paruchury, S.; Sharma, T.; Marathe, P.; Mandlekar, S. Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: In vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm. Drug Dispos., 2015, 36(6), 385-397.
[89]
Babusis, D.; Phan, T.K.; Lee, W.A.; Watkins, W.J.; Ray, A.S. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol. Pharm., 2013, 10, 459-466.
[90]
Pan-Zhou, X-R.; Mayes, B.A.; Rashidzadeh, H.; Gasparac, R.; Smith, S.; Bhadresa, S.; Gupta, K.; Cohen, M.L.; Bu, C.; Good, S.S.; Moussa, A.; Rush, R. Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2′-methylguanosine-5′-monophosphate, in the monkey and formulation optimization for human exposure. Eur. J. Drug Metab. Pharmacokinet., 2016, 41(5), 567-574.
[91]
Grime, K.; Paine, S.W. Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement. Drug Metab. Dispos., 2013, 41, 372-378.
[92]
Kimoto, E.; Bi, Y-A.; Kosa, R.E.; Tremaine, L.M.; Varma, M.V.S. Hepatobiliary clearance prediction: species scaling from monkey, dog, and rat, and in vitro-in vivo extrapolation of sandwich-cultured human hepatocytes using 17 drugs. J. Pharm. Sci., 2017, 106, 2795-2804.
[93]
Nishimuta, H.; Houston, J.B.; Galetin, A. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: Implications for in vitro-in vivo extrapolation of clearance of prodrugs. Drug Metab. Dispos., 2014, 42, 1522-1531.
[94]
Umehara, K-I.; Zollinger, M.; Kigondu, E.; Witschi, M.; Juif, C.; Huth, F.; Schiller, H.; Chibale, K.; Camenisch, G. Esterase phenotyping in human liver in vitro: Specificity of carboxylesterase inhibitors. Xenobiotica, 2016, 46, 862-867.
[95]
Bohnert, T.; Patel, A.; Templeton, I.; Chen, Y.; Lu, C.; Lai, G.; Leung, L.; Tse, S.; Einolf, H.J.; Wang, Y-H.; Sinz, M.; Stearns, R.; Walsky, R.; Geng, W.; Sudsakorn, S.; Moore, D.; He, L.; Wahlstrom, J.; Keirns, J.; Narayanan, R.; Lang, D.; Yang, X. Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-an industry perspective. Drug Metab. Dispos., 2016, 44, 1399-1423.
[96]
Yang, X.; Atkinson, K.; Di, L. Novel cytochrome p450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. Drug Metab. Dispos., 2016, 44, 460-465.
[97]
Fukami, T.; Kariya, M.; Kurokawa, T.; Iida, A.; Nakajima, M. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. Eur. J. Pharm. Sci., 2015, 78, 47-53.
[98]
Shimizu, M.; Fukami, T.; Nakajima, M.; Yokoi, T. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab. Dispos., 2014, 42, 1103-1109.
[99]
Bruckmueller, H.; Martin, P.; Kaehler, M.; Haenisch, S.; Ostrowski, M.; Drozdzik, M.; Siegmund, W.; Cascorbi, I.; Oswald, S. Clinically relevant multidrug transporters are regulated by microRNAs along the human intestine. Mol. Pharm., 2017, 14, 2245-2253.
[100]
Mueller, J.; Keiser, M.; Drozdzik, M.; Oswald, S. Expression, regulation and function of intestinal drug transporters: An update. Biol. Chem., 2017, 398, 175-192.
[101]
Berggren, S.; Gall, C.; Wollnitz, N.; Ekelund, M.; Karlbom, U.; Hoogstraate, J.; Schrenk, D.; Lennernaes, H. Gene and protein expression of P-Glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm., 2007, 4, 252-257.
[102]
Peters, S.A.; Jones, C.R.; Ungell, A-L.; Hatley, O.J.D. Predicting drug extraction in the human gut wall: Assessing contributions from drug metabolizing enzymes and transporter proteins using preclinical models. Clin. Pharmacokinet., 2016, 55, 673-696.
[103]
Strassburg, C.P.; Kneip, S.; Topp, J.; Obermayer-Straub, P.; Barut, A.; Tukey, R.H.; Manns, M.P. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J. Biol. Chem., 2000, 275, 36164-36171.
[104]
Zhang, Q-Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L.S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos., 1999, 27, 804-809.
[105]
Harwood, M.D.; Neuhoff, S.; Carlson, G.L.; Warhurst, G.; Rostami-Hodjegan, A. Absolute abundance and function of intestinal drug transporters: A prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm. Drug Dispos., 2013, 34, 2-28.
Download PDF Flyer